1 / 29

Nucleotide-based therapeutic agents

Nucleotide-based therapeutic agents. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES. Biologic instability. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES. Biologic instability Cellular targeting Uptake Efflux from endosomes. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES.

love
Download Presentation

Nucleotide-based therapeutic agents

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nucleotide-based therapeutic agents

  2. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES Biologic instability

  3. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES Biologicinstability Cellulartargeting Uptake Effluxfromendosomes

  4. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES Biologicinstability Cellulartargeting Uptake Effluxfromendosomes Appropriate controls

  5. RNA INTERFERENCE: siRNA & miRNA

  6. CALAA-01 (Calando Pharmaceuticals) siRNA inhibiting tumor growth via RNA interference to reduce expression of the M2 subunit of ribonucleotide reductase (R2).

  7. HOW CAN WE SELECTIVELY TARGET TUMOR RELEVANT DEFECTS? INIBIT GENE EXPRESSION INIBIT PROTEIN FUNCTION Small molecule inhibitors AS-ODN mAbs siRNA

More Related